163 related articles for article (PubMed ID: 26233434)
1. Design, synthesis and biological characterization of selective LIMK inhibitors.
Boland S; Bourin A; Alen J; Geraets J; Schroeders P; Castermans K; Kindt N; Boumans N; Panitti L; Vanormelingen J; Fransen S; Van de Velde S; Defert O
Bioorg Med Chem Lett; 2015 Sep; 25(18):4005-10. PubMed ID: 26233434
[TBL] [Abstract][Full Text] [Related]
2. Discovery of bis-aryl urea derivatives as potent and selective Limk inhibitors: Exploring Limk1 activity and Limk1/ROCK2 selectivity through a combined computational study.
Cui J; Ding M; Deng W; Yin Y; Wang Z; Zhou H; Sun G; Jiang Y; Feng Y
Bioorg Med Chem; 2015 Dec; 23(23):7464-77. PubMed ID: 26545798
[TBL] [Abstract][Full Text] [Related]
3. Tetrahydropyridine LIMK inhibitors: Structure activity studies and biological characterization.
Champiré A; Berabez R; Braka A; Cosson A; Corret J; Girardin C; Serrano A; Aci-Sèche S; Bonnet P; Josselin B; Brindeau P; Ruchaud S; Leguevel R; Chatterjee D; Mathea S; Knapp S; Brion R; Verrecchia F; Vallée B; Plé K; Bénédetti H; Routier S
Eur J Med Chem; 2024 May; 271():116391. PubMed ID: 38669909
[TBL] [Abstract][Full Text] [Related]
4. Bis-aryl urea derivatives as potent and selective LIM kinase (Limk) inhibitors.
Yin Y; Zheng K; Eid N; Howard S; Jeong JH; Yi F; Guo J; Park CM; Bibian M; Wu W; Hernandez P; Park H; Wu Y; Luo JL; LoGrasso PV; Feng Y
J Med Chem; 2015 Feb; 58(4):1846-61. PubMed ID: 25621531
[TBL] [Abstract][Full Text] [Related]
5. Identification of 5,6-substituted 4-aminothieno[2,3-d]pyrimidines as LIMK1 inhibitors.
Sleebs BE; Nikolakopoulos G; Street IP; Falk H; Baell JB
Bioorg Med Chem Lett; 2011 Oct; 21(19):5992-4. PubMed ID: 21852129
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the rational design and development of LIM kinase inhibitors are not enough to enter clinical trials.
Manetti F
Eur J Med Chem; 2018 Jul; 155():445-458. PubMed ID: 29908439
[TBL] [Abstract][Full Text] [Related]
7. Theoretical study on the interaction of pyrrolopyrimidine derivatives as LIMK2 inhibitors: insight into structure-based inhibitor design.
Shen M; Zhou S; Li Y; Li D; Hou T
Mol Biosyst; 2013 Oct; 9(10):2435-46. PubMed ID: 23881296
[TBL] [Abstract][Full Text] [Related]
8. ROCK inhibitors 3: Design, synthesis and structure-activity relationships of 7-azaindole-based Rho kinase (ROCK) inhibitors.
Bandarage UK; Cao J; Come JH; Court JJ; Gao H; Jacobs MD; Marhefka C; Nanthakumar S; Green J
Bioorg Med Chem Lett; 2018 Aug; 28(15):2622-2626. PubMed ID: 30082069
[TBL] [Abstract][Full Text] [Related]
9. Tofacitinib and analogs as inhibitors of the histone kinase PRK1 (PKN1).
Ostrovskyi D; Rumpf T; Eib J; Lumbroso A; Slynko I; Klaeger S; Heinzlmeir S; Forster M; Gehringer M; Pfaffenrot E; Bauer SM; Schmidtkunz K; Wenzler S; Metzger E; Kuster B; Laufer S; Schüle R; Sippl W; Breit B; Jung M
Future Med Chem; 2016 Sep; 8(13):1537-51. PubMed ID: 27572962
[TBL] [Abstract][Full Text] [Related]
10. Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.
Green J; Cao J; Bandarage UK; Gao H; Court J; Marhefka C; Jacobs M; Taslimi P; Newsome D; Nakayama T; Shah S; Rodems S
J Med Chem; 2015 Jun; 58(12):5028-37. PubMed ID: 26039570
[TBL] [Abstract][Full Text] [Related]
11. ROCK inhibitors 4: Structure-activity relationship studies of 7-azaindole-based rho kinase (ROCK) inhibitors.
Bandarage UK; Court J; Gao H; Nanthakumar S; Come JH; Giroux S; Green J
Bioorg Med Chem Lett; 2021 Feb; 33():127721. PubMed ID: 33259926
[TBL] [Abstract][Full Text] [Related]
12. Effect of the structure of adenosine mimic of bisubstrate-analog inhibitors on their activity towards basophilic protein kinases.
Enkvist E; Kriisa M; Roben M; Kadak G; Raidaru G; Uri A
Bioorg Med Chem Lett; 2009 Nov; 19(21):6098-101. PubMed ID: 19800227
[TBL] [Abstract][Full Text] [Related]
13. Amino acid derived quinazolines as Rock/PKA inhibitors.
Chowdhury S; Chen YT; Fang X; Grant W; Pocas J; Cameron MD; Ruiz C; Lin L; Park H; Schröter T; Bannister TD; Lograsso PV; Feng Y
Bioorg Med Chem Lett; 2013 Mar; 23(6):1592-9. PubMed ID: 23416002
[TBL] [Abstract][Full Text] [Related]
14. Modulation of cofilin phosphorylation by inhibition of the Lim family kinases.
He L; Seitz SP; Trainor GL; Tortolani D; Vaccaro W; Poss M; Tarby CM; Tokarski JS; Penhallow B; Hung CY; Attar R; Lin TA
Bioorg Med Chem Lett; 2012 Sep; 22(18):5995-8. PubMed ID: 22902653
[TBL] [Abstract][Full Text] [Related]
15. Discovery of potent and selective urea-based ROCK inhibitors: Exploring the inhibitor's potency and ROCK2/PKA selectivity by 3D-QSAR, molecular docking and molecular dynamics simulations.
Mei D; Yin Y; Wu F; Cui J; Zhou H; Sun G; Jiang Y; Feng Y
Bioorg Med Chem; 2015 May; 23(10):2505-17. PubMed ID: 25882521
[TBL] [Abstract][Full Text] [Related]
16. Development of pyridopyrimidines as potent Akt1/2 inhibitors.
Wu Z; Hartnett JC; Neilson LA; Robinson RG; Fu S; Barnett SF; Defeo-Jones D; Jones RE; Kral AM; Huber HE; Hartman GD; Bilodeau MT
Bioorg Med Chem Lett; 2008 Feb; 18(4):1274-9. PubMed ID: 18249537
[TBL] [Abstract][Full Text] [Related]
17. Targeting ROCK/LIMK/cofilin signaling pathway in cancer.
Lee MH; Kundu JK; Chae JI; Shim JH
Arch Pharm Res; 2019 Jun; 42(6):481-491. PubMed ID: 31030376
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of 4-quinazolinones as Rho kinase inhibitors.
Fang X; Chen YT; Sessions EH; Chowdhury S; Vojkovsky T; Yin Y; Pocas JR; Grant W; Schröter T; Lin L; Ruiz C; Cameron MD; LoGrasso P; Bannister TD; Feng Y
Bioorg Med Chem Lett; 2011 Mar; 21(6):1844-8. PubMed ID: 21349713
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma.
Abbhi V; Saini L; Mishra S; Sethi G; Kumar AP; Piplani P
Bioorg Med Chem; 2017 Nov; 25(21):6071-6085. PubMed ID: 29033348
[TBL] [Abstract][Full Text] [Related]
20. Design of Aminobenzothiazole Inhibitors of Rho Kinases 1 and 2 by Using Protein Kinase A as a Structure Surrogate.
Judge RA; Vasudevan A; Scott VE; Simler GH; Pratt SD; Namovic MT; Putman CB; Aguirre A; Stoll VS; Mamo M; Swann SI; Cassar SC; Faltynek CR; Kage KL; Boyce-Rustay JM; Hobson AD
Chembiochem; 2018 Mar; 19(6):613-621. PubMed ID: 29314498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
